These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 28071698)

  • 1. Increased levels of CSF total but not oligomeric or phosphorylated forms of alpha-synuclein in patients diagnosed with probable Alzheimer's disease.
    Majbour NK; Chiasserini D; Vaikath NN; Eusebi P; Tokuda T; van de Berg W; Parnetti L; Calabresi P; El-Agnaf OM
    Sci Rep; 2017 Jan; 7():40263. PubMed ID: 28071698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia.
    Chiasserini D; Biscetti L; Eusebi P; Salvadori N; Frattini G; Simoni S; De Roeck N; Tambasco N; Stoops E; Vanderstichele H; Engelborghs S; Mollenhauer B; Calabresi P; Parnetti L
    Alzheimers Res Ther; 2017 Jul; 9(1):52. PubMed ID: 28750675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson's disease.
    Majbour NK; Vaikath NN; van Dijk KD; Ardah MT; Varghese S; Vesterager LB; Montezinho LP; Poole S; Safieh-Garabedian B; Tokuda T; Teunissen CE; Berendse HW; van de Berg WD; El-Agnaf OM
    Mol Neurodegener; 2016 Jan; 11():7. PubMed ID: 26782965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CSF α-synuclein improves diagnostic and prognostic performance of CSF tau and Aβ in Alzheimer's disease.
    Toledo JB; Korff A; Shaw LM; Trojanowski JQ; Zhang J
    Acta Neuropathol; 2013 Nov; 126(5):683-97. PubMed ID: 23812319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cerebrospinal fluid α-synuclein contributes to the differential diagnosis of Alzheimer's disease.
    Shi M; Tang L; Toledo JB; Ginghina C; Wang H; Aro P; Jensen PH; Weintraub D; Chen-Plotkin AS; Irwin DJ; Grossman M; McCluskey L; Elman LB; Wolk DA; Lee EB; Shaw LM; Trojanowski JQ; Zhang J
    Alzheimers Dement; 2018 Aug; 14(8):1052-1062. PubMed ID: 29604263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measurement of CSF α-synuclein improves early differential diagnosis of mild cognitive impairment due to Alzheimer's disease.
    García-Ayllón MS; Monge-Argilés JA; Monge-García V; Navarrete F; Cortés-Gómez MA; Sánchez-Payá J; Manzanares J; Gasparini-Berenguer R; Leiva-Santana C; Sáez-Valero J
    J Neurochem; 2019 Jul; 150(2):218-230. PubMed ID: 31077373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The value of cerebrospinal fluid α-synuclein and the tau/α-synuclein ratio for diagnosis of neurodegenerative disorders with Lewy pathology.
    Førland MG; Tysnes OB; Aarsland D; Maple-Grødem J; Pedersen KF; Alves G; Lange J
    Eur J Neurol; 2020 Jan; 27(1):43-50. PubMed ID: 31293044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased CSF α-synuclein levels in Alzheimer's disease: correlation with tau levels.
    Slaets S; Vanmechelen E; Le Bastard N; Decraemer H; Vandijck M; Martin JJ; De Deyn PP; Engelborghs S
    Alzheimers Dement; 2014 Oct; 10(5 Suppl):S290-8. PubMed ID: 24439167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CSF levels of the neuronal injury biomarker visinin-like protein-1 in Alzheimer's disease and dementia with Lewy bodies.
    Luo X; Hou L; Shi H; Zhong X; Zhang Y; Zheng D; Tan Y; Hu G; Mu N; Chan J; Chen X; Fang Y; Wu F; He H; Ning Y
    J Neurochem; 2013 Dec; 127(5):681-90. PubMed ID: 23800322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of cerebrospinal fluid α-synuclein with total and phospho-tau
    Vergallo A; Bun RS; Toschi N; Baldacci F; Zetterberg H; Blennow K; Cavedo E; Lamari F; Habert MO; Dubois B; Floris R; Garaci F; Lista S; Hampel H; ;
    Alzheimers Dement; 2018 Dec; 14(12):1623-1631. PubMed ID: 30055132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CSF biomarkers β-amyloid, tau proteins and a-synuclein in the differential diagnosis of Parkinson-plus syndromes.
    Constantinides VC; Paraskevas GP; Emmanouilidou E; Petropoulou O; Bougea A; Vekrellis K; Evdokimidis I; Stamboulis E; Kapaki E
    J Neurol Sci; 2017 Nov; 382():91-95. PubMed ID: 29111028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.
    Mollenhauer B; Locascio JJ; Schulz-Schaeffer W; Sixel-Döring F; Trenkwalder C; Schlossmacher MG
    Lancet Neurol; 2011 Mar; 10(3):230-40. PubMed ID: 21317042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss?
    Ohrfelt A; Grognet P; Andreasen N; Wallin A; Vanmechelen E; Blennow K; Zetterberg H
    Neurosci Lett; 2009 Feb; 450(3):332-5. PubMed ID: 19022350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cerebrospinal fluid β-synuclein as a synaptic biomarker for preclinical Alzheimer's disease.
    Barba L; Abu Rumeileh S; Bellomo G; Paolini Paoletti F; Halbgebauer S; Oeckl P; Steinacker P; Massa F; Gaetani L; Parnetti L; Otto M
    J Neurol Neurosurg Psychiatry; 2023 Jan; 94(1):83-86. PubMed ID: 35944974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CSF α-synuclein does not discriminate dementia with Lewy bodies from Alzheimer's disease.
    Reesink FE; Lemstra AW; van Dijk KD; Berendse HW; van de Berg WD; Klein M; Blankenstein MA; Scheltens P; Verbeek MM; van der Flier WM
    J Alzheimers Dis; 2010; 22(1):87-95. PubMed ID: 20847452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential levels of alpha-synuclein, beta-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease.
    Kasuga K; Tokutake T; Ishikawa A; Uchiyama T; Tokuda T; Onodera O; Nishizawa M; Ikeuchi T
    J Neurol Neurosurg Psychiatry; 2010 Jun; 81(6):608-10. PubMed ID: 20522869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurogranin as a Novel Biomarker in Alzheimer's Disease.
    Agnello L; Gambino CM; Lo Sasso B; Bivona G; Milano S; Ciaccio AM; Piccoli T; La Bella V; Ciaccio M
    Lab Med; 2021 Mar; 52(2):188-196. PubMed ID: 32926148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The diagnostic value of CSF α-synuclein in the differential diagnosis of dementia with Lewy bodies vs. normal subjects and patients with Alzheimer's disease.
    Kapaki E; Paraskevas GP; Emmanouilidou E; Vekrellis K
    PLoS One; 2013; 8(11):e81654. PubMed ID: 24282614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential Diagnostic Value of Red Blood Cells α-Synuclein Heteroaggregates in Alzheimer's Disease.
    Baldacci F; Daniele S; Piccarducci R; Giampietri L; Pietrobono D; Giorgi FS; Nicoletti V; Frosini D; Libertini P; Lo Gerfo A; Petrozzi L; Donadio E; Betti L; Trincavelli ML; Siciliano G; Ceravolo R; Tognoni G; Bonuccelli U; Martini C
    Mol Neurobiol; 2019 Sep; 56(9):6451-6459. PubMed ID: 30826968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T1rho MRI and CSF biomarkers in diagnosis of Alzheimer's disease.
    Haris M; Yadav SK; Rizwan A; Singh A; Cai K; Kaura D; Wang E; Davatzikos C; Trojanowski JQ; Melhem ER; Marincola FM; Borthakur A
    Neuroimage Clin; 2015; 7():598-604. PubMed ID: 25844314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.